首页> 外文期刊>Protein Science: A Publication of the Protein Society >Human soluble epoxide hydrolase: structural basis of inhibition by 4-(3-cyclohexylureido)-carboxylic acids.
【24h】

Human soluble epoxide hydrolase: structural basis of inhibition by 4-(3-cyclohexylureido)-carboxylic acids.

机译:人可溶性环氧化物水解酶:被4-(3-环己基脲基)-羧酸抑制的结构基础。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

X-ray crystal structures of human soluble epoxide hydrolase (sEH) complexed with four different dialkylurea inhibitors bearing pendant carboxylate "tails" of varying length have been determined at 2.3-3.0 A resolution. Similarities among inhibitor binding modes reinforce the proposed roles of Y381 and/or Y465 as general acids that protonate the epoxide ring of the substrate in concert with nucleophilic attack of D333 at the electrophilic epoxide carbon. Additionally, the binding of these inhibitors allows us to model the binding mode of the endogenous substrate 14,15-epoxyeicosatrienoic acid. Contrasts among inhibitor binding modes include opposite orientations of inhibitor binding in the active-site hydrophobic tunnel. Alternative binding orientations observed for this series of inhibitors to human sEH, as well as the binding of certain dialkylurea inhibitors to human sEH and murine sEH, complicate the structure-based design of human sEH inhibitors with potential pharmaceutical applications in the treatment of hypertension. Thus, with regard to the optimization of inhibitor designs targeting human sEH, it is critical that human sEH and not murine sEH be utilized for inhibitor screening, and it is critical that structures of human sEH-inhibitor complexes be determined to verify inhibitor binding orientations that correlate with measured affinities.
机译:已在2.3-3.0 A的分辨率下确定了与四种带有不同长度的侧链羧酸盐“尾部”的不同二烷基脲抑制剂复合的人类可溶性环氧化物水解酶(sEH)的X射线晶体结构。抑制剂结合模式之间的相似性增强了Y381和/或Y465作为一般酸的拟议作用,该一般酸与D333在亲电子环氧碳上的亲核攻击相协调,使底物的环氧环质子化。此外,这些抑制剂的结合使我们能够模拟内源性底物14,15-环氧二十碳三烯酸的结合模式。抑制剂结合模式之间的对比包括活性位点疏水通道中抑制剂结合的相反方向。在这一系列抑制剂与人sEH上观察到的其他结合方向以及某些二烷基脲抑制剂与人sEH和鼠类sEH的结合使人sEH抑制剂的基于结构的设计在治疗高血压方面可能具有药物应用。因此,关于针对人sEH的抑制剂设计的优化,至关重要的是将人sEH而非鼠类sEH用于抑制剂筛选,并且至关重要的是确定人sEH-抑制剂复合物的结构以验证抑制剂的结合方向。与测得的亲和力相关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号